Compare BridgeBio Pharma Inc (BBIO) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Vanguard Real Estate Index Fund ETF — how do they compare? BridgeBio Pharma Inc trades at $84.58 (market cap $16.36B), while Vanguard Real Estate Index Fund ETF trades at $97.25. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, Vanguard Real Estate Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | VNQ | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | — |
52-Week High | $90.17 | $100.95 |
52-Week Low | $47.29 | $87.00 |
Enterprise Value | $18.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
VNQ (Vanguard Real Estate ETF) trades at $96.745, down 0.38% on the day amid a bearish technical signal. The ETF shows mixed momentum with oversold short-term RSI readings but bearish moving averages. Recent institutional selling activity from firms like Bank of America and City Holding Co. indicates cautious positioning in the real estate sector. The fund's dividend yield remains a key attraction for income-focused investors.
The outlook for VNQ is challenged by rising interest rate sensitivity and institutional outflows, though the oversold RSI suggests potential for near-term stabilization. Investors should weigh the ETF's low expense ratio and U.S. REIT diversification against sector-specific headwinds including commercial real estate pressures and economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
